Latest Oncology News

EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer

EC-18 Reduces Duration and Incidence of Chemoradiation-Induced Oral Mucositis in Head and Neck Cancer

October 21st 2021

Kristi Rosa

Treatment with the small molecule oral immunomodulator EC-18 resulted in a reduction in both the duration and incidence of severe oral mucositis in patients with head and neck cancer who are undergoing concurrent chemoradiation.

Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients

Abid on Optimizing COVID-19 Vaccines in CAR T-Cell Therapy Recipients

October 21st 2021

OncLive Staff

Dr. Abid discusses immune-compromising factors that are indigenous to CAR T-cell therapy recipients, the immunogenic potential of different COVID-19 vaccines, determinants of vaccine responses, and the potential need for booster vaccine dosing in this population.

TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL

TG-1701 Induces Strong Response Rates, Fewer AEs in Relapsed/Refractory CLL

October 21st 2021

Maggie Tibbitt

Chan Cheah, MBBS, discusses TG-1701 as a more target-specific BTK inhibitor, the outcomes in response rates in the cohorts of the trial, and where future research is headed with this agent.

Mutational Status Is Associated With Time to First Treatment in Newly Diagnosed CLL

Mutational Status Is Associated With Time to First Treatment in Newly Diagnosed CLL

October 21st 2021

Caroline Seymour

The presence of at least 1 mutation captured by next-generation sequencing was associated with a shorter time to first treatment among patients with newly diagnosed chronic lymphocytic leukemia, particularly those with mutations in POT1, ATM, FBXW7, and MYD88 genes.

Nivolumab/Chemo Approved in Europe for HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

Nivolumab/Chemo Approved in Europe for HER2– Advanced or Metastatic Gastric, GEJ, or Esophageal Adenocarcinoma

October 21st 2021

Kristi Rosa

The European Commission has approved nivolumab plus fluoropyrimidine- and platinum-based chemotherapy for the frontline treatment of adult patients with HER2-negative advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma whose tumors have a PD-L1 combined positive score of 5 or higher.

Latest Oncology Videos

All Oncology News

Dr. Brown on the Clinical Implications of the PRIMA Trial in Ovarian Cancer

October 5th 2021

Jubilee Brown, MD

Jubilee Brown, MD, discusses the clinical implications of the phase 3 PRIMA trial in advanced ovarian cancer.

Triplet Combo Produces Promising Preliminary Activity in BRAF V600E–Mutant Metastatic CRC

October 5th 2021

Courtney Marabella

The triplet combination comprised of encorafenib, binimetinib, and cetuximab elicited encouraging responses with a manageable safety profile in patients with previously untreated BRAF V600E–mutant metastatic colorectal cancer, meeting the primary end point of the phase 2 ANCHOR-CRC trial.

Key Advances Showcase the Potential of Precision Medicine in NSCLC

October 5th 2021

Caroline Seymour

The sustainability of next-generation sequencing will be dependent on the implementation of thorough informatics and infrastructure that can support the integration of genomic results into electronic medical records.

Florida Cancer Specialists & Research Institute Leaders Serve on Faculty for Value-Based Cancer Care Summit

October 5th 2021

Senior leaders of Florida Cancer Specialists & Research Institute have been invited to serve on the faculty for the Association for Value-Based Cancer Care 2021 Summit & Educational Program being held in New York, NY on Oct. 13 – 15.

FDA Grants Breakthrough Therapy Designation to Repotrectinib for NTRK+ TKI-Pretreated Advanced Solid Tumors

October 5th 2021

Kristi Rosa

The FDA has granted a breakthrough therapy designation to repotrectinib as a potential therapeutic option for patients with advanced solid tumors that harbor an NTRK gene fusion who have progressed after treatment with 1 or 2 prior TRK TKIs, with or without prior chemotherapy, and who have no satisfactory alternative options.

Monk Reviews Transformative KEYNOTE-826 Data in Cervical Cancer and Next Steps for Research

October 5th 2021

Maggie Tibbitt

Bradley J. Monk, MD, FACS, FACOG, discusses the practice-changing data from KEYNOTE-826 examining pembrolizumab plus chemotherapy with or without bevacizumab and next steps for research in recurrent or metastatic cervical cancer.

Sacituzumab Govitecan Significantly Improves HRQoL Vs Physician’s Choice in mTNBC

October 5th 2021

Courtney Marabella

Sacituzumab govitecan-hziy resulted in a statistically significant and clinically meaningful improvement in health-related quality of life compared with single-agent chemotherapy of physician’s choice in patients with metastatic triple-negative breast cancer.

Enfortumab Vedotin Challenges Standard of Care in Urothelial Carcinoma

October 5th 2021

OncLive Staff

Two indications have been granted by the FDA to the Nectin-4directed antibody, enfortumab vedotin-ejfv, marking a shift in the treatment landscape for patients with advanced urothelial carcinoma.

Amivantamab Plus Lazertinib Demonstrates Activity After Osimertinib and/or Chemo in EGFR-Mutant NSCLC

October 5th 2021

Jessica Hergert

Amivantamab-vmjw in combination with lazertinib demonstrated significant clinical activity with durable responses in patients with EGFR-mutated non–small cell lung cancer who had progressed on osimertinib.

Dr. Nassif on the Efficacy of Early-Phase Clinical Trials in Soft Tissue Sarcoma

October 4th 2021

Elise Nassif, MD

Elise Nassif, MD, discusses the efficacy of early-phase clinical trials in soft tissue sarcoma.

Dr. Rimawi on Mitigating Interstitial Lung Disease in HER2+ Breast Cancer

October 4th 2021

Mothaffar F. Rimawi, MD

Mothaffar Fahed Rimawi, MD, discusses mitigating interstitial lung disease/pneumonitis in HER2-positive breast cancer.

Dr. Hamilton on the Potential Integration of Novel SERDs in ER+/HER2- Breast Cancer

October 4th 2021

Erika P. Hamilton, MD

Erika P. Hamilton, MD, discusses the potential integration of novel selective estrogen receptor degraders into the treatment armamentarium for ER-positive, HER2-negative breast cancer.

Dr. Vose on the Use of CAR T-Cell Therapy in Non-Hodgkin Lymphoma

October 4th 2021

Julie M. Vose, MD

Julie M. Vose, MD, MBA, discusses the use of CAR T-cell therapy in non-Hodgkin lymphoma.

Dr. Salani on the Rationale for Immunotherapy/PARP Inhibitor Combos in Ovarian Cancer

October 4th 2021

Ritu Salani, MD

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

Treatment Should Not Be Dependent on Age in Soft Tissue Sarcoma

October 4th 2021

Caroline Seymour

Soft tissue sarcoma was the primary cause of death in patients over the age of 75 years, indicating that age alone should not be a prohibitive factor for treatment in older patients, according to findings from a retrospective analysis that was presented at the 2021 ESMO Congress.

See All News